- Home
- MLCO vs DMRA Comparison
MLCO vs DMRA Comparison
Compare MLCO & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MLCO | DMRA |
|---|---|---|
| Founded | 2003 | 2011 |
| Country | Hong Kong | United States |
| Employees | 22961 | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2006 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MLCO | DMRA |
|---|---|---|
| Price | $4.24 | $21.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 10 |
| Target Price | $7.06 | ★ $46.89 |
| AVG Volume (30 Days) | ★ 1.8M | 682.3K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 121.48 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.93 | N/A |
| Revenue Next Year | $4.38 | N/A |
| P/E Ratio | $12.16 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.07 | $16.50 |
| 52 Week High | $9.53 | $34.89 |
Technical Indicators
Market Signals| Indicator | MLCO | DMRA |
|---|---|---|
| Relative Strength Index (RSI) | 32.92 | 42.87 |
| Support Level | $4.07 | $18.99 |
| Resistance Level | $5.73 | $26.76 |
| Average True Range (ATR) | 0.15 | 1.42 |
| MACD | -0.01 | 0.23 |
| Stochastic Oscillator | 24.24 | 65.04 |
Price Performance
Historical ComparisonAbout MLCO Melco Resorts & Entertainment Limited
Melco Resorts & Entertainment is one of only six licensed casino operators in Macao. It operates Altira, a complex focused on premium customers; City of Dreams, an integrated resort in Cotai serving both mass-market and premium patrons; and Mocha Clubs' electronic gaming machines. The company also has a majority interest in Studio City, which opened in 2015. Outside Macao, Melco owns City of Dreams Manila in the Philippines and City of Dreams Mediterranean in Cyprus. The business mix in terms of adjusted EBITDA was about 84% from Macao, with the rest from overseas as of 2025.
About DMRA Damora Therapeutics Inc. Common Stock
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.